Skip to main content
Health Podcast Library
Episode 332

Measuring Stress: The Missing Vital Sign That Triples Treatment Success with Dr. Andrew Holman

Episode Description

This episode’s Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow’ Sustainability Campaign, and how you can get involved: CLICK HERE

Episode Overview:

Stress is the missing vital sign that determines whether treatments succeed or fail.

Our next guest, Dr. Andrew Holman, is tackling this challenge as CEO of Inmedix. With 25 years of clinical experience as a practicing rheumatologist, Andrew possesses a unique perspective bridging medicine and diagnostics innovation.

Watching billions wasted annually on autoimmune treatments that fail, he developed the CloudHRV platform to measure stress biology with medical-grade precision in just five minutes.

Driven by a passion to end the trial-and-error cycle plaguing chronic disease care, Andrew shares how Inmedix tripled remission rates in rheumatoid arthritis patients from 25% to 79%.

Join us to discover how stress biology is transforming precision medicine and unlocking new outcomes for the 15 million Americans living with autoimmune diseases. Let's go!

Episode Highlights:

  1. FOUNDER WISDOM: Surround yourself with smarter people who tell you straight where your strengths and weaknesses are.
  2. ORIGIN STORY: A $10 million patent sale at age 46 came from championing fibromyalgia patients when they were dismissed by medicine.
  3. CLINICAL BREAKTHROUGH: The FDA-cleared CloudHRV platform tripled remission rates from 25% to 79% by measuring stress biology.
  4. FUTURE OF MEDICINE: Autonomic nervous system science may be to this century what antibiotics were to the last.
  5. PASSIONATE PIONEER MOMENT: "I try to be a learn-it-all instead of a know-it-all."

About our Guest:

Dr. Andrew Holman is the CEO of Inmedix. He is a practicing rheumatologist with 25 years of clinical experience who discovered the missing link in healthcare: stress—the unmeasured vital sign that determines whether treatments work or fail.

As a physician watching 75% of autoimmune treatments fail while $10 billion is wasted annually on ineffective drugs, he developed Inmedix's FDA-cleared CloudHRV platform to measure stress biology with medical-grade precision in just 5 minutes. His clinical trials tripled remission rates in rheumatology from 25% to 79%, transforming medicine from trial-and-error to precision care in a $3.1 billion market.

Dr. Holman brings proven commercial execution alongside clinical expertise: he leads a team with decades of experience scaling diagnostics companies through IPOs and acquisitions at Myriad Genetics, Crescendo Bioscience, and Exagen.

Links Supporting This Episode:

  1. Inmedix Website: CLICK HERE
  2. Dr. Andrew Holman LinkedIn page: CLICK HERE
  3. Mike Biselli LinkedIn page: CLICK HERE
  4. Mike Biselli Twitter page: CLICK HERE
  5. Visit our website: CLICK HERE
  6. Subscribe to newsletter: CLICK HERE
  7. Guest nomination form: CLICK HEREE
  8. Guest nomination form: CLICK HERE

Proudly Supported by

BetterHelpForvis MazarsAAOSCalendarPAmowPod

Patrons of Health Podcast Library

AAOS Career Podcast
Achieving Health
AAOS Now Podcast
OrthoInfo
Who the Health Cares? with Prof Michael Sparer
Aging Like a Pro
Stronger After Stroke

Supporting Shows

Thriving with Addiction with Dr. Jonathan Avery
Impulse | Meeting Healthcare Pioneers
HITea With Grace
Faces of Digital Health
Beyond The Paper Gown Podcast
Coaching Healthcare Leaders
Nurse Rosa's INsights
Beyond Clinical Walls
Hopeful Hints
Cuts and Consults
On the Pulse Podcast
Coffee Break: Breaking the Cycle of Bullying in Healthcare, One Cup at a Time
Healthcare for Humans
Speak Up For Your Health
HIT Like a Girl Pod: Empowering Women in Health IT
This Just In Radio Show

We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies